🇺🇸·6h agoIndustry
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Publisher
A
AbbVie News
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AbbVie News
- Region
- USA
- Scope
- Industry
- Published
- July 17, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.abbvie.com
Leave the platform to read the original full article on the publisher site.
Source: AbbVie News
Scope: Industry
Related coverage
More related coverage
Certara/2h ago
From Dosimetry to Dose Decisions How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development
Amneal Pharmaceuticals RSS/6h ago
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
GSK News/9h ago
GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
WuXi Biologics/9h ago